Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir

Journal of Nanoparticle Research

Volumn 16, Issue 1, 2014, Pages

  Jain, Nivrati ^a   Rajoriya, Vaibhav ^a   Jain, Prateek Kumar ^a   Jain, Ashish Kumar ^a  

^a ADINA Institute of Pharmaceutical Sciences   (India)

Author keywords

Acyclovir; Asialoglycoprotein receptor; Hepatocytes targeting; Lactosaminated chitosan nanoparticles; Lactose conjugation; N succinyl chitosan

Indexed keywords

ACYCLOVIR; ASIALOGLYCOPROTEIN RECEPTORS; CHITOSAN NANOPARTICLES; HEPATOCYTES; LACTOSE CONJUGATION;

CHITOSAN; NANOPARTICLES; SUGARS; ZETA POTENTIAL;

VIRUSES;

ACICLOVIR; CHITOSAN; LACTOSAMINATED N SUCCINYL CHITOSAN NANOPARTICLE; LACTOSE; LIGAND; NANOCARRIER; SODIUM; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DISPERSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TISSUE LEVEL; FLUORESCENCE MICROSCOPY; GELATION; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; POLYDISPERSITY INDEX; PRIORITY JOURNAL; TARGET CELL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84888783204     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-2136-x     Document Type: Article

References (24)

1. Agrawal P, Gupta U, Jain NK (2007) Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28:3349-3359
2. Bhadra D, Yadav AK, Bhadra S, Jain NK (2005) Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 295:221-233
3. Borch RF, Bernstein MD, Durst HD (1971) The cyanohydridoborate anion as a selective reducing agent. J Am Chem Soc 93:2897-2904
4. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carrier. J Appl Poly Sci 63:125-132
5. Griffiths PD (2009) A perspective on antiviral resistance. J Clin Virol 46:3-8
6. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80 coated nanoparticles. Pharm Res 16:1564-1569
7. Jayaseelan S, Suresh S, Sathishkumar G, Sekar V, Perumal P (2010) Bioanalytical method development and validation of lamivudine by RP-HPLC method. Int J Chem Tech Res 2:163-167
8. Kato Y, Onishi H, Machida Y (2000a) Evaluation of N-succinyl-chitosan as a systemic long circulating polymer. Biomaterials 21:1579-1585
9. Kato Y, Onishi H, Machida Y (2000b) Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Rel 70:295-307
10. Kato Y, Onishi H, Machida Y (2003) Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotech 7:303-309
11. Kauper P, Rossi N, Laue C, Schmitt F, Lagopoulos L, Juillerat L, Wandrey C (2007) Chitosan based nanoparticles for medical applications: stability in physiological environments. Eur Cel Mat 13:3-4
12. Kawakami S, Yamashita F, Nishikawa M, Takakura Y, Hashida M (1998) Asialoglycoprotein receptor mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun 252:78-83
13. Lin WJ, Chen MH (2006) Synthesis of multifunctional chitosan with galactose as a targeting ligand for glycoprotein receptor. Carbohydr Polym 67:474-480
14. Mandloi DK, Tyagi PK, Rai VK, Dey S, Ashada RK, Mohanraj P (2009) Method development and validation of RP-HPLC in the application of in vitro dissolution study of lamivudine in bulk drug and tablet formulation. J Chem Pharm Res 1:286-296
15. Mao SJ, Hou SX, He R, Zhang LK, Wei DP, Bi YQ, Jin H (2005) Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes. World J Gastroenterol 11:3075-3079
16. McMahon BJ, Doo E (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49(5):45-55
17. Mourya VK, Inamdar NN (2008) Chitosan-modifications and applications: opportunities galore. React Funct Polym 68(6):1013-1051
18. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP (2009) Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Targ 17(10):777-787
19. Reddy LH, Murthy RSR (2004) Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap 148(2):161-166
20. Song Y, Onishi H, Nagai T (1993) Conjugate of mitomycin C with N-succinyl-chitosan: in vitro drug release properties, toxicity and antitumor activity. Int J Pharm 98:121-130
21. Tu J, Zhong S, Li P (2004) Studies on acyclovir dextran conjugate synthesis and pharmacokinetics. Drug Dev Ind Pharm 3:959-965
22. Utreja S, Jain NK (2001) Advances in controlled and novel drug delivery. CBS Publishers, New Delhi
23. Wu J, Nantz MH, Zern MA (2002) Targeting hepatocytes for drug and gene delivery: emerging novel approach and applications. Frontiers Biosci 7:717-725
24. Zhang ZR, He Q (1999) Study on liver targeting and hepatocytes permeability of acyclovir via polybutylcyanoacrylate nanoparticles. World J Gastroenterol 5(4):330-333